Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Aprea Therapeutics ( (APRE) ).
On March 16, 2026, Aprea reported fourth-quarter and full-year 2025 results and highlighted early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the Phase 1 ACESOT-1051 trial, where two PPP2R1A-mutated endometrial cancer patients achieved unconfirmed partial responses by February 2026 and five additional patients showed stable disease, with a favorable safety profile observed during dose escalation. The company set the Phase 2 dose for ATRN-119, then paused further monotherapy enrollment to pursue combination strategies, completed two private placements raising about $8.7 million, appointed Eugene Kennedy as Chief Medical Advisor, and ended 2025 with $14.6 million in cash and a reduced quarterly operating loss, stating that existing funds and January 2026 proceeds should support operations into the first quarter of 2027.
The most recent analyst rating on (APRE) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.
Spark’s Take on APRE Stock
According to Spark, TipRanks’ AI Analyst, APRE is a Neutral.
APRE scores low primarily due to weak financial performance (ongoing losses and cash burn with declining revenue) and bearish technicals (trading below key moving averages with negative MACD). Valuation provides limited support given negative earnings and no dividend yield data.
To see Spark’s full report on APRE stock, click here.
More about Aprea Therapeutics
Aprea Therapeutics, Inc. is a clinical-stage precision oncology company developing targeted therapies for patients with biomarker-defined cancers. Its pipeline includes APR-1051, an oral WEE1 inhibitor, and ATRN-119, a macrocyclic ATR inhibitor, aimed at tumors with DNA damage response gene alterations and high unmet medical need.
Average Trading Volume: 2,208,770
Technical Sentiment Signal: Sell
Current Market Cap: $8.43M
Learn more about APRE stock on TipRanks’ Stock Analysis page.